2005 Annual Report
Our Technology
Achievements: Past 12 Months
Letter To Shareholders
TAP
We believe that interest in immunoconjugate drugs for the treatment of cancer will expand dramtically in the future, and that ImmunoGen will gain increasing recognition for the value of its immunoconjugate technology.
Operations
ImmunoGen Annual Report 2005

2005 Annual Report
Our Technology
Achievements: Past 12 Months
Letter To Shareholders
Operations

2005 Annual Report
Our Technology
Achievements: Past 12 Months
Letter To Shareholders
Operations
Corporate Information
10 K